@LDuska profile picture
Linda Duska @LDuska
Joined March 2013
  • Tweets 175
  • Following 69
  • Followers 305
3 Photos and videos
Linda Duska retweeted
Moffitt Cancer Center
@MoffittNews
15 Mar 2025
During the #SGOMtg, Linda Duska, MD (@LDuska) from @uvamedicine shares encouraging insights into the overall survival and progression-free survival results from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study based on the second interim analysis. #MoffittSGO25 #SGO2025 #SGOAM2025 #MultipleYourImpact #CancerResearch #CervicalCancer
3
10
1,065
Linda Duska retweeted
OncLive.com
@OncLive
16 Mar 2025
Our first interview of the day was with @LDuska of @uvamedicine, who shared key OS and PFS2 data from the second interim analysis of the KEYNOTE-A18 study. Hear a brief preview of her research below, and check out onclive.com for more details! @SGO_org #SGOMtg #gynsm
0:21
6
14
1,576
Linda Duska retweeted
SGO@SGO_org
15 Oct 2024
The SGO released a clinical practice advisory addressing the nationwide shortage of intravenous (IV) solutions. These guidelines outline strategy considerations to manage the shortage in various settings while maintaining high-quality patient care. shorturl.at/q75yR
3
4
770
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
Dr Eskander - Beware of Harkening #IGCS2024 @SGO_org @GOG Important to interpret post hoc analyses with caution
5
7
969
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
Wow Drop the mic moment Dr Ramez!!!! Review of DUO-E and KN-B21
2
7
15
2,435
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
KN-B21 dMMR cohort highly positive πŸ‘πŸ€©πŸ₯°#IGCS2024 @SGO_org @GOG
7
9
1,104
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
KN-B21 subgroup analysis of dMMR cohort - highly anticipated! #IGCS2024 @SGO_org @GOG
6
8
671
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
Dr Westin present post hoc DUO-E exploratory analysis of biomarkers- high degree of heterogeneity with significant overlap. #IGCS2024 @SGO_org @GOG
6
8
906
Linda Duska retweeted
Susan Zweizig@SusanZweizig
16 Oct 2024
#IGCS 2024 Thoughtful, excellent distillation by Dr Ramez Eskander on role of IO in endometrial cancer including the unknown, encourages care in interpreting data @SGO_org @UMassChan
4
11
593
Linda Duska retweeted
rcoledude@rcoledude
16 Oct 2024
Congratulations Shannon on updated results on DUO-E at #igcs2024
7
29
1,594
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
Dr Noelle Cloven - reassuring QoL data for patients on RUBY trial - the trifecta- improved PFS, OS, and QoL. #IGCS2024 @SGO_org @GOG
6
10
651
Linda Duska retweeted
Shannon Westin, MD, MPH, FASCO@ShannonWestin
16 Oct 2024
πŸŽ‰A clear win at #IGCS2024!! Cadonilimab added to chemotherapy yielded improved improved progression free and overall in recurrent #cervicalcancer #gyncsm
7
33
3,169
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
Exciting poster presentations - video with Dr Brown capturing her thoughts on the BOUQUET trial πŸ’β€οΈπŸ’
0:53
6
10
730
Linda Duska retweeted
Angeles Secord@AngelesSecord
16 Oct 2024
Dr Jubilee Brown presents BOUQUET data at #IGCS2024 @SGO_org @GOG Rare tumors are important to study and yes - clinical trials are feasible. Love the biomarker data ❀️
8
36
1,411
Linda Duska retweeted
Debra Richardson, M.D.@DebbieRic23
15 Sep 2024
FIH SHR A1921 ADC targets tropical 2. Dose optimization in ovarian cancer 3mg/kg and 2mg/kg cohorts. Exciting response rate and PFS- 7.9 months 3mg/kg and 6.9 mg/kg for the 2mg/kg. Stomatitis common. @SGO_org @myESMO #ESMO2024
3
5
434
Linda Duska retweeted
Debra Richardson, M.D.@DebbieRic23
14 Sep 2024
A18 show OS benefit for addition of pembrolizumab to chemort in cervical cancer. HR 0.67. @SGO_org @myESMO #ESMO2024
7
24
1,749
Linda Duska retweeted
Floor Backes@FBackesMD
14 Sep 2024
avelumab MTX was suggested as the new standard regimen for low risk GTD. Exciting >95% durable cure rate in stage 1-3, WHO score 1-6. @myESMO @SGO_org #esmo2024
5
14
535
Linda Duska retweeted
Debra Richardson, M.D.@DebbieRic23
14 Sep 2024
ATHENA- combo is negative. The addition of nivolumab to rucaparib was not better than rucaparib maintenance alone. The combo was more toxic. @SGO_org @myESMO
1
3
300
Linda Duska retweeted
Angeles Secord@AngelesSecord
21 Oct 2023
Congratulations Dr Westin and all DUO-E investigator!! Provocative data regarding combination durva olaparib in patients with endometrial cancer - role of biomarkers??to direct combination vs IO only maintenance therapy. Impressive PFS!
1
6
550
Linda Duska retweeted
Angeles Secord@AngelesSecord
21 Oct 2023
What’s Happening at ESMO!!It was my honor and pleasure to sit down with Dr. Shannon Westin and talk about DUO- E. Check out this video from your friendly SGO reporter @SGO_org @GOG #ESMO23
0:24
3
5
34
3,398
Load more